Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic tripeptide
Vesugen is a marketed name for the tripeptide KED, studied in vascular-cell and limited clinical research.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Vesugen is a marketed name for KED, a three-amino-acid peptide studied in vascular cells and limited regional clinical research. It is not FDA approved.
Researchers have explored whether KED changes vascular-cell markers or outcomes linked to blood-vessel function. The clinical question requires blinded comparisons and validated vascular endpoints.
A 41-patient report evaluated KED-containing treatment in men with vasculogenic erectile dysfunction and described clinical and laboratory changes. The study was small and lacked the safeguards of a large modern randomized trial. Laboratory work explored gene and chromatin markers in cultured cells.
Whether the clinical findings reproduce under blinded randomized conditions, whether KED itself caused them, how the peptide behaves in humans, and what the short- and long-term safety profile is remain unresolved. Cell markers do not establish vascular benefit.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A small clinical report investigated KED-containing treatment in men with vasculogenic erectile dysfunction and measured clinical and laboratory outcomes.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Small uncontrolled or weakly controlled human evidence plus laboratory studies.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Whether findings reproduce under blinded randomized conditions and translate to validated vascular outcomes.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The study was small, regional, and did not use a robust blinded placebo-controlled design. It cannot establish a causal KED effect, general vascular benefit, product equivalence, or long-term safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
A 41-patient clinical report evaluated KED in vasculogenic erectile dysfunction without the safeguards of a large modern randomized trial.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether findings reproduce under blinded randomized conditions and translate to validated vascular outcomes.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
A small report in vasculogenic erectile dysfunction and cell-aging experiments provide early signals. Neither establishes broad vascular rejuvenation or product equivalence.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Small clinical study without robust placebo control
Men with vasculogenic erectile dysfunction
A 41-patient report described clinical and laboratory outcomes after KED-containing treatment.
Study administration: Not stated in the current record.
Limitations: Small, regional, incompletely controlled report; requires independent randomized replication.
Human-cell culture study
Population not stated.
Endpoints were not fully described in the current record.
KED-related laboratory work explored gene and chromatin markers in cultured cells.
Study administration: Not stated in the current record.
Limitations: Mechanistic cell evidence is not a clinical vascular outcome.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA-approved; limited regional human evidence. Whether findings reproduce under blinded randomized conditions and translate to validated vascular outcomes.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 25051774
PMID 25051766